Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines

Boston Children'S Hospital, Boston MA

Investigators

Abstract

To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines for vaccine recipients of different ages, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.